CMB 305

Drug Profile

CMB 305

Alternative Names: CMB-305; ID-CMB305; LV 305 + G 305

Latest Information Update: 21 Jun 2017

Price : $50

At a glance

  • Originator Immune Design
  • Developer Genentech; Immune Design
  • Class Cancer vaccines; Peptide vaccines; Peptides; RNA; RNA vaccines
  • Mechanism of Action Dendritic cell stimulants; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Soft tissue sarcoma
  • New Molecular Entity No

Highest Development Phases

  • Phase II Soft tissue sarcoma
  • Phase I Solid tumours

Most Recent Events

  • 05 Jun 2017 Adverse events, efficacy and immunogenicity data from a phase I trial in Solid tumours presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
  • 30 May 2017 Immune Design completes enrolment in its phase I trial for Solid tumours (Monotherapy, Locally recurrent, Metastatic disease, In adults, In elderly) in USA (NCT02387125)
  • 18 May 2017 Adverse events and efficacy data from a clinical trial in Soft tissue sarcoma released by Immune Design
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top